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Abstract
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A number of topoisomerase II-targeted anticancer drugs, including amsacrine, utilize an acridine
or related aromatic core as a scaffold. Therefore, to further explore the potential of acridine-related
compounds to act as topoisomerase II poisons, we synthesized a series of novel
trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-one derivatives and examined their ability
to enhance DNA cleavage mediated by human topoisomerase IIα. Derivatives containing a H, Cl,
F, and Br at C7 enhanced enzyme-mediated double-stranded DNA cleavage ~5.5- to 8.5-fold over
baseline, but were less potent than amsacrine. The inclusion of an amino group at C9 was critical
for activity. The compounds lost their activity against topoisomerase IIα in the presence of a
reducing agent, displayed no activity against the catalytic core of topoisomerase IIα, and inhibited
DNA cleavage when incubated with the enzyme prior to the addition of DNA. These findings
strongly suggest that the compounds act as covalent, rather than interfacial, topoisomerase II
poisons.
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Eukaryotic type II topoisomerases are ubiquitous enzymes that play critical roles in a
number of genetic processes, including DNA replication, transcription, recombination, and
chromosome segregation.1–6 These enzymes resolve the problems associated with the
topological constraints of DNA (i.e., under- or overwinding, knotting, and tangling) by
transiently cleaving both strands of the double helix.1–6 Humans encode two type II
topoisomerase isoforms, topoisomerase IIα and IIβ.
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Topoisomerase IIα is essential for the survival of proliferating cells, increases in
concentration over the cell cycle (peaking in G2/M), and is the isoform that is involved in
replicative processes. In contrast, topoisomerase IIβ is non-essential at the cellular level, is
expressed in proliferating and quiescent cells, and maintains a constant expression level
throughout the cell cycle. Although the precise cellular function of topoisomerase IIβ is not
well defined, it appears to play an important role in the expression of hormonally regulated
genes.1–5
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Type II topoisomerases are the target for a number of widely used anticancer drugs.1,2,7–10
These drugs function by an insidious mechanism. Rather than robbing the cell of essential
topoisomerase II functions, they act by increasing levels of covalent topoisomerase IIcleaved DNA complexes (i.e., cleavage complexes), which are requisite intermediates in the
catalytic cycle of the enzyme. Because these agents convert the type II enzymes into cellular
toxins that fragment the genome, they are called topoisomerase II poisons to distinguish
them from catalytic inhibitors. Topoisomerase IIα is an important cytotoxic target for
anticancer drugs.
Amsacrine was the first anticancer agent shown to act by poisoning topoisomerase II.11 The
drug is composed of an acridine ring coupled to a 4′-amino-methane-sulfon-m-anisidide
head group. Structure-activity studies suggest that the poisoning activity of amsacrine is
embodied in the head group, while the acridine moiety enhances drug activity primarily by
promoting strong interactions with DNA.12
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A number of other topoisomerase II-targeted agents also utilize an acridine or related
aromatic core.1,2,7–10,13 Although most of these drug cores are attached to an aromatic head
group, some agents (such as mitoxantrone) lack a head group entirely. Therefore, to further
explore the potential of acridine-related compounds to act as topoisomerase II poisons, we
synthesized a series of novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones
(referred to as trifluoromethylated 9-amino acridin-2-ones) and analyzed the activity of these
compounds against human topoisomerase IIα. The trifluoromethyl group at C3 was included
to provide additional H-bonding groups and because the presence of fluorines often provides
improved pharmacological properties, such as increased membrane permeability, enhanced
hydrophobic binding interactions, and improved metabolic stability (discussed in Fadeyi et
al.14). The syntheses of these compounds started with the corresponding
enaminobenzonitrile14 utilizing the generalized scheme shown in Fig. 1. Structures of the
trifluoromethylated acridin-2-ones, along with that of amsacrine for comparison, are shown
in Fig. 2. The detailed syntheses and physical and chemical characterizations of the
compounds are described in the accompanying Supplementary Data.
As a first step toward analyzing the effects of the trifluoromethylated acridin-2-one
derivatives on human topoisomerase IIα, we determined the ability of these compounds to
enhance enzyme-mediated double-stranded cleavage of negatively supercoiled DNA (Fig.
3). Several of the trifluoromethylated acridin-2-one derivatives induced high levels of
enzyme-mediated DNA cleavage, although none were as potent as amsacrine or etoposide
(another well-characterized topoisomerase II poison). Acridine, which represents the
aromatic core of amsacrine, did not enhance DNA cleavage. On the basis of the cleavage
data, a number of structure-activity relationships among the compounds became evident.
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First, the presence of the 9-amino moiety was critical for the activity of the
trifluoromethylated acridin-2-one derivatives. Removal of this group (converting compound
1 to compound 7) decreased cleavage enhancement from >8-fold to ~1.5-fold and increased
the CC3 (level of compound required to triple baseline levels of cleavage complex; used as a
measure of potency because this value is within the linear range of activity for the
compounds examined) from 155 µM to >>1000 µM. Second, the inclusion of either a methyl
group at C6 (compound 2) or a nitro moiety at C7 (compound 5) was deleterious and
decreased both the level of DNA cleavage and the potency of the compounds. Third, the
inclusion of halogens at C7 affected the activity of the compounds against topoisomerase
IIα. The presence of Cl, F, or Br (compounds 3, 4, or 6, respectively) resulted in a modest
reduction (<35%) in cleavage levels (at 1000 µM compound) compared to compound 1.
However, the chloro- and bromo-substituted compounds displayed an ~1.8-fold increase in
potency. In contrast, the potency of the fluoro-substituted compound decreased ~3.4-fold.
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In some cases, enhanced interactions between topoisomerase II poisons and DNA leads to
greater drug activity against the enzyme. Therefore, the ability of the trifluoromethylated
acridin-2-one derivatives to intercalate into DNA was assessed (Fig. 4). In the concentration
range examined, the compounds were weak intercalators at best (as determined by the shift
in DNA topoisomer bands toward the position of negatively supercoiled DNA). Furthermore,
there does not appear to be any correlation between the ability of the trifluoromethylated
acridin-2-ones to intercalate and their activity against topoisomerase IIα. Compounds 2 and
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4, for example, displayed similar DNA cleavage enhancement but very different intercalation
patterns. Furthermore, compound 5 displayed similar intercalation to compound 1, but had a
significantly lower potency against topoisomerase IIα. Because compounds 5 and 7
displayed virtually no activity against topoisomerase IIα, they were not subjected to further
analysis.
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Clinically relevant topoisomerase II-targeted drugs, such as amsacrine and etoposide, act as
interfacial topoisomerase II poisons.15 These drugs interact at the enzyme-DNA interface in
a noncovalent fashion, intercalate into the cleaved DNA scissile bond, and stabilize the
cleavage complex by inhibiting the ability of the type II enzyme to ligate the DNA
backbone. Therefore, to determine whether the trifluoromethylated 9-amino acridin-2-one
derivatives act by a similar mechanism, the effects of these compounds on topoisomerase
IIα-mediated DNA ligation were characterized (Fig. 5). In marked contrast to amsacrine and
etoposide, none of the trifluoromethylated 9-amino acridin-2-ones that enhanced DNA
cleavage had any significant effect on rates of ligation.
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The lack of ligation inhibition does not preclude the possibility that the trifluoromethylated
9-amino acridin-2-one derivatives act as interfacial poisons. However, the finding suggests
that these compounds may increase levels of topoisomerase IIα-DNA cleavage complexes
by a different mechanism. As an alternative to the interfacial mechanism, a number of
topoisomerase II poisons act through covalent interactions with the type II enzyme. Covalent
poisons adduct topoisomerase II at cysteine (and potentially other) residues outside of the
DNA cleavage-ligation active site of the enzyme.2,16–19 They appear to increase levels of
cleavage complexes by altering the ability of the N-terminal domain of topoisomerase II to
act as a protein clamp.20,21 Covalent poisons display several hallmark characteristics that
distinguish them from interfacial poisons.16,20,22–26 Because covalent poisons are reactive
and require redox cycling as part of the adduction reaction, their activities are abrogated by
the presence of reducing agents. Furthermore, because covalent poisons act by altering the
N-terminal portion of the enzyme, they do not enhance DNA cleavage by topoisomerase II
constructs that lack this domain. Finally, although covalent poisons enhance DNA scission
when added to the topoisomerase II-DNA complex, they irreversibly inhibit enzymemediated cleavage when incubated with the protein prior to the addition of DNA. This likely
occurs (at least in part) through the closing of the N-terminal protein gate, which precludes
the binding of circular DNAs by the enzyme.
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In order to identify the mechanism by which the trifluoromethylated 9-amino acridin-2-one
derivatives alter topoisomerase II function, we first determined the effects of dithiothreitol
(DTT) on the ability of these compounds to enhance topoisomerase IIα-mediated DNA
cleavage (Fig. 6). The reducing agent dramatically decreased levels of acridin-2-one-induced
DNA cleavage. In contrast, DTT had no effect on the activity of the interfacial poison
amsacrine. These results strongly suggest that the trifluoromethylated 9-amino acridin-2-one
derivatives alter topoisomerase IIα-mediated DNA cleavage by acting as covalent poisons.
Therefore, two additional experiments were carried out to confirm this mechanism.
We assessed the effects of the trifluoromethylated 9-amino acridin-2-one derivatives on the
catalytic core of topoisomerase IIα, a construct that lacks both the C- and N-terminal
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domains (Fig. 7). Although interfacial poisons such as amsacrine maintain their activity
against the catalytic core, the trifluoromethylated 9-amino acridin-2-one derivatives did not
induce enzyme-mediated DNA cleavage above background levels. As a final experiment, the
trifluoromethylated 9-amino acridin-2-one derivatives were incubated with topoisomerase
IIα prior to the addition of DNA (Fig. 8). All of the compounds rapidly inhibited the DNA
cleavage activity of the enzyme.
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Taken together, the above experiments strongly suggest that the trifluoromethylated 9-amino
acridin-2-one derivatives enhance topoisomerase IIα-mediated DNA cleavage by acting as
covalent topoisomerase II poisons. The chemistry that underlies the adduction of
topoisomerase IIα by the acridin-2-ones is not immediately apparent. However, given the
essential nature of the 9-amino moiety for the activity of these compounds, it may involve
amino-imino tautomerism or the hydrolysis of the amino group to form a more reactive
species. It is notable that the 4′-amino-methane-sulfon-m-anisidide head group of amsacrine
(which also includes a primary aromatic amine) displays the ability to act as a covalent
topoisomerase II poison.
On the basis of comparisons to amsacrine, it will be interesting to determine whether the
addition of a head group to the acridin-2-one derivatives at the 9-amino position will convert
these compounds to interfacial poisons that could act as scaffolds for the development of
novel topoisomerase II-targeted drugs.
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Figure 1.
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Generalized scheme used to synthesize the trifluoromethylated acridin-2-one derivatives
used in the current study.
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Figure 2.

Structures of amsacrine (left) and the trifluoromethylated acridin-2-ones used in the current
study. The trifluoromethylated acridin-2-one skeleton is shown (top right) and the
substituents at positions R1–3 (red) for compounds 1–7 are listed in the table.
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Figure 3.

Effects of trifluoromethylated acridin-2-one derivatives on the DNA cleavage activity of
human topoisomerase IIα (left). Results with amsacrine, etoposide, and acridine as shown
as controls. Activity is reported as the relative increase in double-stranded DNA (dsDNA)
cleavage as compared to reactions carried out in the absence of compounds. Error bars
represent the standard deviation of at least three independent experiments. The table (right)
provides the concentrations (CC3) of compounds 1–7, acridine, amsacrine, and etoposide
that are required to triple levels of cleavage complexes as compared to baseline levels
generated in the absence of the compounds. These values are used as a measure of potency.
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Figure 4.
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Intercalation of trifluoromethylated acridin-2-one derivatives. Results of a topoisomerase IDNA relaxation assay are shown. Intercalation is indicated by the shift in the position of the
plasmid from relaxed (Rel) DNA, which is generated upon incubation of negatively
supercoiled DNA (-SC) with topoisomerase I. Each lane is labeled with the number of the
trifluoromethylated acridin-2-one compound that was tested. Three intercalators, acridine
(Acr, 500 µM), ethidium bromide (EtBr, 10 µM), and amsacrine (AMSA, 500 µM), and a
non-intercalator, etoposide (Etop, 500 µM), are shown as positive and negative controls,
respectively. Assays that contained only -SC DNA (DNA) or -SC DNA and topoisomerase I
with no compound (TopI) are shown. Gel is representative of three independent experiments.
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Figure 5.

Effects of trifluoromethylated 9-amino acridin-2-one derivatives on DNA ligation mediated
by topoisomerase IIα. Reaction mixtures were carried out in the absence or presence of 1
mM compound. Reactions that contained 50 µM amsacrine or etoposide are shown as
positive controls. Error bars represent the standard deviation of at least three independent
experiments.
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Figure 6.

Effects of a reducing agent (DTT) on acridin-2-one-induced DNA cleavage mediated by
topoisomerase IIα. DNA cleavage reactions were carried out in the presence of 1 mM
trifluoromethylated 9-amino acridin-2-one derivatives in the absence (green) or presence
(blue) of 0.5 mM DTT. Reactions carried out in the absence of compounds (hTIIα) or in the
presence of 50 µM amsacrine (AMSA) are shown as controls. Error bars represent the
standard deviation of at least three independent experiments.
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Figure 7.

Effects of trifluoromethylated 9-amino acridin-2-one derivatives on DNA cleavage mediated
by the catalytic core of topoisomerase IIα. DNA cleavage reactions using full-length
topoisomerase IIα (green) or the catalytic core of the enzyme (blue) were carried out in the
presence of 1 mM acridin-2-one derivatives. Reactions carried out in the absence of
compounds (hTIIα) or in the presence of 50 µM amsacrine (AMSA) are shown as controls.
Baseline levels of DNA cleavage mediated by the catalytic core are lower than those
observed for the intact enzyme. Error bars represent the standard deviation of at least three
independent experiments.
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Figure 8.

Effects of trifluoromethylated 9-amino acridin-2-one derivatives on DNA cleavage mediated
by topoisomerase IIα when incubated with the enzyme prior to the addition of DNA.
Cleavage reactions were initiated after topoisomerase IIα was incubated with 1 mM
derivatives for 1–5 min. The inset displays an expansion of time points between 0–1 min for
compounds 1, 2, 3, and 6. Error bars represent the standard deviation of at least three
independent experiments.
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